Vital Therapies (VTL) Tops Q2 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Vital Therapies (VTL) Tops Q2 EPS by 3c

Vital Therapies Announces Second Quarter 2018 Financial Results

August 7, 2018 4:01 PM EDT

SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the second quarter ended June 30, 2018.

This is an exciting time for the Company. We are diligently working toward database lock for VTL-308 and expect to report topline results in the second half of September, said Russell J. Cox, the Companys Chief Executive Officer. Additionally, we continue with preparations for the potential submission of a biologics license application and... More